Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) Shares Outstanding (Weighted Average) (2016 - 2024)

Historic Shares Outstanding (Weighted Average) for Lexaria Bioscience (LEXX) over the last 14 years, with Q2 2024 value amounting to $13.9 million.

  • Lexaria Bioscience's Shares Outstanding (Weighted Average) rose 11510.96% to $13.9 million in Q2 2024 from the same period last year, while for May 2024 it was $13.9 million, marking a year-over-year increase of 11510.96%. This contributed to the annual value of $6.6 million for FY2023, which is 1238.39% up from last year.
  • Lexaria Bioscience's Shares Outstanding (Weighted Average) amounted to $13.9 million in Q2 2024, which was up 11510.96% from $10.8 million recorded in Q1 2024.
  • In the past 5 years, Lexaria Bioscience's Shares Outstanding (Weighted Average) ranged from a high of $13.9 million in Q2 2024 and a low of $2.7 million during Q1 2020
  • Over the past 5 years, Lexaria Bioscience's median Shares Outstanding (Weighted Average) value was $5.9 million (recorded in 2022), while the average stood at $5.9 million.
  • In the last 5 years, Lexaria Bioscience's Shares Outstanding (Weighted Average) plummeted by 9656.18% in 2020 and then surged by 11510.96% in 2024.
  • Quarter analysis of 5 years shows Lexaria Bioscience's Shares Outstanding (Weighted Average) stood at $3.0 million in 2020, then surged by 90.8% to $5.7 million in 2021, then grew by 3.92% to $6.0 million in 2022, then skyrocketed by 52.1% to $9.1 million in 2023, then skyrocketed by 53.07% to $13.9 million in 2024.
  • Its last three reported values are $13.9 million in Q2 2024, $10.8 million for Q1 2024, and $9.1 million during Q4 2023.